GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ARYx Therapeutics Inc (OTCPK:ARYX) » Definitions » Scaled Net Operating Assets

ARYx Therapeutics (ARYx Therapeutics) Scaled Net Operating Assets : 0.33 (As of Sep. 2010)


View and export this data going back to 2007. Start your Free Trial

What is ARYx Therapeutics Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

ARYx Therapeutics's operating assets for the quarter that ended in Sep. 2010 was $3.02 Mil. ARYx Therapeutics's operating liabilities for the quarter that ended in Sep. 2010 was $1.39 Mil. ARYx Therapeutics's Total Assets for the quarter that ended in Jun. 2010 was $5.02 Mil. Therefore, ARYx Therapeutics's scaled net operating assets (SNOA) for the quarter that ended in Sep. 2010 was 0.33.


ARYx Therapeutics Scaled Net Operating Assets Historical Data

The historical data trend for ARYx Therapeutics's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ARYx Therapeutics Scaled Net Operating Assets Chart

ARYx Therapeutics Annual Data
Trend Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09
Scaled Net Operating Assets
Get a 7-Day Free Trial - -4.03 -0.37 -0.01 0.02

ARYx Therapeutics Quarterly Data
Dec05 Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 0.06 0.06 0.04 0.33

Competitive Comparison of ARYx Therapeutics's Scaled Net Operating Assets

For the Drug Manufacturers - Specialty & Generic subindustry, ARYx Therapeutics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ARYx Therapeutics's Scaled Net Operating Assets Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ARYx Therapeutics's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where ARYx Therapeutics's Scaled Net Operating Assets falls into.



ARYx Therapeutics Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

ARYx Therapeutics's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2009 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2009 )
=(Operating Assets (A: Dec. 2009 )-Operating Liabilities (A: Dec. 2009 ))/Total Assets (A: Dec. 2008 )
=(4.644-3.498)/51.148
=0.02

where

Operating Assets(A: Dec. 2009 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=12.406 - 7.762
=4.644

Operating Liabilities(A: Dec. 2009 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=15.322 - 6.641 - 5.183
=3.498

ARYx Therapeutics's Scaled Net Operating Assets (SNOA) for the quarter that ended in Sep. 2010 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Sep. 2010 )
=(Operating Assets (Q: Sep. 2010 )-Operating Liabilities (Q: Sep. 2010 ))/Total Assets (Q: Jun. 2010 )
=(3.018-1.387)/5.018
=0.33

where

Operating Assets(Q: Sep. 2010 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=5.972 - 2.954
=3.018

Operating Liabilities(Q: Sep. 2010 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=13.707 - 5.495 - 6.825
=1.387

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ARYx Therapeutics Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of ARYx Therapeutics's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


ARYx Therapeutics (ARYx Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
6300 Dumbarton Circle, Fremont, CA, USA, 94555
ARYx Therapeutics Inc is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates designed to eliminate known safety issues associated with well-established, commercially successful drugs.
Executives
Newhall Charles W Iii 10 percent owner 1119 ST PAUL ST, BALTIMORE MD 21202
C Richard Kramlich 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Ryan D Drant 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202
Krishna Kittu Kolluri 10 percent owner
New Enterprise Associates 12, Limited Partnership 10 percent owner 1119 ST. PAUL STREET, BALTIMORE MD 21202
Nea Partners 12, Limited Partnership 10 percent owner 1119 ST. PAUL STREET, BALTIMORE MD 21202
Nea 12 Gp, Llc 10 percent owner 1119 ST. PAUL STREET, BALTIMORE MD 21202
Mark W Perry 10 percent owner
Patrick J Kerins 10 percent owner
Forest Baskett 10 percent owner
Growth Equity Opportunities Fund, Llc 10 percent owner 1119 ST. PAUL STREET, BALTIMORE MD 21202
Peter J Barris 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202
M James Barrett 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202
Scott D Sandell 10 percent owner
Nicholas Galakatos 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116

ARYx Therapeutics (ARYx Therapeutics) Headlines

No Headlines